{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:35:32Z","timestamp":1768473332428,"version":"3.49.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Spinal Cord Ser Cases"],"DOI":"10.1038\/s41394-021-00442-1","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T13:07:14Z","timestamp":1629810434000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A severe case of non-infective myositis six weeks post intramuscular injections of Onabotulinum toxin A (Botox) in a young man with tetraplegia: case report"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6244-6372","authenticated-orcid":false,"given":"Roxana Edith","family":"Heriseanu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyadarshini","family":"Chari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"442_CR1","unstructured":"American Spinal Injury Association. International Standards for Neurological Classification of Spinal Cord Injury. Richmond, VA: American Spinal Injury Association; 2019."},{"key":"442_CR2","unstructured":"Bono CM, Vives MJ, Kauffman CP Cervical Injuries: Indications and Options for Surgery. In: Lin V, editor. Spinal Cord Medicine Principles and Practice: Demos Medical Publishing; 2003. p. 132."},{"key":"442_CR3","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/0140-6736(90)90389-m.","volume":"335","author":"JW Lance","year":"1990","unstructured":"Lance JW. What is spasticity? Lancet. 1990;335:606 https:\/\/doi.org\/10.1016\/0140-6736(90)90389-m.","journal-title":"Lancet."},{"key":"442_CR4","doi-asserted-by":"publisher","first-page":"354906","DOI":"10.1155\/2014\/354906.","volume":"2014","author":"C Trompetto","year":"2014","unstructured":"Trompetto C, Marinelli L, Mori L, Pelosin E, Curr\u00e0 A, Molfetta L, et al. Pathophysiology of spasticity: implications for neurorehabilitation. Biomed Res Int. 2014;2014:354906 https:\/\/doi.org\/10.1155\/2014\/354906.","journal-title":"Biomed Res Int"},{"key":"442_CR5","unstructured":"Horn LJ, Singh G, Dabrowski E Chemoneurolysis With Phenol and Alcohol: A Dying Art That Merits Revival. In: Brashear A, Elovic E, editors. Spasticity Diagnosis and Management: Demos Medical Publishing; 2011. p. 101-19."},{"key":"442_CR6","unstructured":"Therapeutic Goods Administration. AusPAR Botox Botulinum toxin, type A Allergan Australia Pty Ltd PM-2012-01467-3-3. Australian Government Department of Health; 2013."},{"key":"442_CR7","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/cei.12194.","volume":"175","author":"PO Carstens","year":"2014","unstructured":"Carstens PO, Schmidt J. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clin Exp Immunol. 2014;175:349\u201358. https:\/\/doi.org\/10.1111\/cei.12194.","journal-title":"Clin Exp Immunol"},{"key":"442_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40674-018-0106-2.","volume":"4","author":"S Barsotti","year":"2018","unstructured":"Barsotti S, Lundberg IE. Current treatment for myositis. Curr Treatm Opt Rheumatol 2018;4:299\u2013315. https:\/\/doi.org\/10.1007\/s40674-018-0106-2.","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"442_CR9","doi-asserted-by":"publisher","first-page":"S274","DOI":"10.1097\/dss.0000000000001414","volume":"43","author":"S Fagien","year":"2017","unstructured":"Fagien S, Cohen JL, Coleman W, Monheit G, Carruthers J, Street J, et al. Forehead line treatment with OnabotulinumtoxinA in subjects with forehead and glabellar facial rhytids: a phase 3 study. Dermatol Surg. 2017;43:S274\u2013s84. https:\/\/doi.org\/10.1097\/dss.0000000000001414. Suppl 3.","journal-title":"Dermatol Surg"},{"key":"442_CR10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1097\/dss.0000000000001612.","volume":"44","author":"K De Boulle","year":"2018","unstructured":"De Boulle K, Werschler WP, Gold MH, Bruce S, Sattler G, Ogilvie P, et al. Phase 3 study of OnabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines. Dermatol Surg. 2018;44:1437\u201348. https:\/\/doi.org\/10.1097\/dss.0000000000001612.","journal-title":"Dermatol Surg"},{"key":"442_CR11","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1007\/s00415-010-5526-3.","volume":"257","author":"R Kaji","year":"2010","unstructured":"Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M. Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010;257:1330\u20137. https:\/\/doi.org\/10.1007\/s00415-010-5526-3.","journal-title":"J Neurol"},{"key":"442_CR12","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.pmrj.2017.12.006.","volume":"10","author":"T Wein","year":"2018","unstructured":"Wein T, Esquenazi A, Jost WH, Ward AB, Pan G, Dimitrova R. OnabotulinumtoxinA for the treatment of poststroke distal lower limb spasticity: a randomized. Trial PM R 2018;10:693\u2013703. https:\/\/doi.org\/10.1016\/j.pmrj.2017.12.006.","journal-title":"Trial PM R"},{"key":"442_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jns.2017.07.031.","volume":"380","author":"A Schrey","year":"2017","unstructured":"Schrey A, Airas L, Jokela M, Pulkkinen J. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. J Neurol Sci. 2017;380:142\u20137. https:\/\/doi.org\/10.1016\/j.jns.2017.07.031.","journal-title":"J Neurol Sci"},{"key":"442_CR14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10072-005-0378-9.","volume":"26","author":"F Mancini","year":"2005","unstructured":"Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005;26:26\u201331. https:\/\/doi.org\/10.1007\/s10072-005-0378-9.","journal-title":"Neurol Sci"},{"key":"442_CR15","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1080\/09638280500404305.","volume":"28","author":"AB Haugh","year":"2006","unstructured":"Haugh AB, Pandyan AD, Johnson GR. A systematic review of the Tardieu Scale for the measurement of spasticity. Disabil Rehabil. 2006;28:899\u2013907. https:\/\/doi.org\/10.1080\/09638280500404305.","journal-title":"Disabil Rehabil"}],"container-title":["Spinal Cord Series and Cases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41394-021-00442-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41394-021-00442-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41394-021-00442-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,30]],"date-time":"2022-11-30T15:08:52Z","timestamp":1669820932000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41394-021-00442-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["442"],"URL":"https:\/\/doi.org\/10.1038\/s41394-021-00442-1","relation":{},"ISSN":["2058-6124"],"issn-type":[{"value":"2058-6124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"30 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}